NASDAQ:MYNZ Mainz Biomed Q2 2025 Earnings Report $1.32 0.00 (0.00%) As of 09/23/2026 ProfileEarnings HistoryForecast Mainz Biomed EPS ResultsActual EPS-$1.33Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AMainz Biomed Revenue ResultsActual Revenue$0.14 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMainz Biomed Announcement DetailsQuarterQ2 2025Date9/26/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Mainz Biomed Earnings HeadlinesCarpenter Technology (NYSE:CRS) versus Mainz Biomed (NASDAQ:MYNZ) Critical ContrastSeptember 20, 2026 | americanbankingnews.comMainz BioMed NV: Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of Directors / Name change to Quantum Cyber (QUCY)March 12, 2026 | finanznachrichten.deReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.September 25 at 1:00 AM | Base Camp Trading (Ad)Strategische Neuausrichtung: Mainz Biomed firmiert in Quantum Cyber um und ernennt neuen ChairmanMarch 11, 2026 | de.investing.comMainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of DirectorsMarch 11, 2026 | globenewswire.comMainz Biomed to Present at the Pancreatic Cancer Session at Digestive Disease Week, Demonstrating Effectiveness of mRNA Biomarkers in Blood SamplesFebruary 24, 2026 | markets.businessinsider.comSee More Mainz Biomed Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Mainz Biomed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mainz Biomed and other key companies, straight to your email. Email Address About Mainz BiomedMainz Biomed (NASDAQ:MYNZ) N.V. is a molecular genetics diagnostics company focused on improving the early detection of colorectal cancer. The company develops noninvasive diagnostic tests designed to identify disease-associated genetic markers from stool samples, with the goal of making screening more accessible and convenient. Its principal product is ColoAlert, a home-based, laboratory-processed stool DNA test for colorectal cancer screening. The test analyzes molecular biomarkers associated with colorectal cancer and advanced adenomas, allowing individuals to collect samples at home and send them to a laboratory for analysis. ColoAlert has been available in Germany and other European markets under applicable regulatory requirements. Mainz Biomed was founded in 2016 and is based in Mainz, Germany. The company has pursued regulatory authorization and commercial expansion in the United States, including clinical development of its ColoAlert technology through the eAArly DETECT study. Mainz Biomed’s broader strategy centers on developing molecular diagnostic products that support earlier cancer detection and complement existing screening methods.View Mainz Biomed ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks3 Restaurant Stocks Near 52-Week Lows as Consumer Pressure BuildsPaychex Plunges, Providing the Entry Investors Have Been Waiting ForThe Case for Buying High-Yield General Mills Just StrengthenedEnergy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock? Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
